Recent developments highlight Mesoblast's clinical trial progress, commercial sales growth, regulatory milestones, and financing activities.

• Mesoblast posted higher revenue and a 44% narrower loss for FY2026 driven by momentum in Ryoncil® sales [N1].
• The company completed patient treatment in the pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain with 350 patients randomized and treated as of August 2026 [N2][S1].
• Mesoblast treated 300 patients in the Phase 3 low back pain trial by July 2026 [N3].
• In June 2026, Mesoblast withdrew $50 million from a five-year non-dilutive credit facility, retiring higher cost debt and eliminating short-term obligations [N4][S1].
• Ryoncil® achieved $30 million in Q1 2026 sales and $30.3 million in Q3 2026 net sales, nearing $100 million in revenue since launch [N5][N1].
• The company reached full enrollment in the Phase 3 back pain study by April 2026 [N6].
• Mesoblast acquired exclusive CAR-MSC technology license from Mayo Clinic in April 2026 to enhance its MSC therapies [N8].
• The FDA granted IND clearance to proceed with a registrational trial of Ryoncil® in Duchenne muscular dystrophy in early 2026 [S1].

Mesoblast has demonstrated commercial traction with Ryoncil® achieving nearly $100 million in revenue since launch and expanding payer coverage. The company has advanced pivotal Phase 3 trials for rexlemestrocel-L in chronic low back pain with patient recruitment and treatment milestones met. Regulatory progress includes FDA BLA filing for an additional indication and IND clearance for Duchenne muscular dystrophy trials. The acquisition of CAR technology from Mayo Clinic may enhance therapeutic efficacy and pipeline potential. Non-dilutive financing facilities have improved the company's capital structure. These factors collectively support the company's ability to expand its product portfolio and commercial footprint.

Mesoblast continues to report net losses and negative earnings per share, reflecting ongoing investment in clinical development and commercialization. The success of pivotal Phase 3 trials and regulatory approvals remains uncertain and subject to clinical and regulatory risks. The company operates in a competitive and highly regulated biotechnology sector with potential challenges in market adoption, reimbursement, and manufacturing scale-up. Dependence on a limited number of products and indications may expose the company to concentration risk. Additionally, the need for continued capital to fund operations may present financial risks despite recent non-dilutive financing.

Mesoblast's moat is anchored in its proprietary allogeneic cell therapy platform and its FDA-approved product Ryoncil®, which has established commercial presence and reimbursement coverage in the US. The company's ongoing pivotal Phase 3 trials and regulatory filings for rexlemestrocel-L in multiple indications support its pipeline depth. Exclusive licensing of CAR technology from Mayo Clinic enhances its technological differentiation. The company's established relationships with transplant centers and payers, along with its regulatory approvals and clinical data, create barriers to entry for competitors in its niche cell therapy markets. Additionally, its strong governance and compliance frameworks support sustainable operations in a highly regulated industry.

• Clinical Trial Risk: Pivotal Phase 3 trials for rexlemestrocel-L in chronic low back pain and other indications may not meet efficacy or safety endpoints required for regulatory approval.
• Regulatory Risk: FDA and other regulatory authorities may delay or deny approvals or impose restrictions impacting product commercialization.
• Commercialization Risk: Market adoption of cell therapy products depends on payer coverage, physician acceptance, and competitive landscape.
• Financial Risk: Continued net losses and need for capital raise may impact financial stability despite recent credit facilities.
• Operational Risk: Manufacturing scale-up and supply chain management for cell therapies are complex and may affect product availability.

• Mesoblast Limited is a publicly listed biotechnology company incorporated in Australia in 2004 and dual-listed on the ASX and Nasdaq since 2015 [S1].
• The company focuses on allogeneic cell therapies targeting serious medical conditions including steroid-refractory acute graft-versus-host disease (SR-aGvHD), cardiovascular diseases, immune-mediated and inflammatory conditions, oncology, hematology, and spine and orthopedic diseases [S1].
• Mesoblast has a recently FDA-approved product, Ryoncil® (remestemcel-L-rknd), commercially launched in March 2025 for children 2 months and older with steroid-refractory acute graft-versus-host disease [S1].
• Ryoncil® has achieved net sales of approximately $30 million in Q1 2026 and $30.3 million in Q3 2026, nearing $100 million in revenue since launch [N5][N9][N1].
• The company is conducting pivotal Phase 3 clinical trials for rexlemestrocel-L (Revascor®) in chronic low back pain (CLBP) associated with degenerative disc disease, with patient recruitment and treatment milestones achieved including 350 patients randomized and treated as of August 2026 [S1][N2][N3].
• Mesoblast received a Biologics License Application (BLA) filing number from the FDA in June 2026 for rexlemestrocel-L in prevention of life-threatening gastrointestinal bleeding in end-stage heart failure patients with left ventricular assist devices [S1].
• The company acquired an exclusive worldwide license to a patented chimeric antigen receptor (CAR) technology platform to enhance mesenchymal stromal cell (MSC) therapies in April 2026 [N8][S1].
• Mesoblast has drawn down $50 million from a five-year non-dilutive credit facility in June 2026, retiring higher cost debt and eliminating short-term debt obligations [N4][S1].
• As of December 31, 2025, Mesoblast reported cash and cash equivalents of $129.975 million, current assets of $202.483 million, current liabilities of $128.069 million, a current ratio of 1.58, and a cash ratio of 1.01 [sec_financial_snapshot].
• For fiscal year 2025, the company reported revenue of $51.342 million and a net loss of $40.162 million, with basic and diluted EPS of -$0.0311 per share [sec_financial_snapshot].
• Mesoblast emphasizes corporate governance, business ethics, risk management, and human capital management, including diversity and inclusion policies, with zero material non-compliance cases reported in FY26 [S1].
• The company has a Code of Business Conduct & Ethics, Anti-Bribery and Anti-Corruption Policy, and an Ethics Hotline for anonymous reporting, with no whistleblower reports in the reporting period [S1].
• Mesoblast's Board oversees ESG-related risks and opportunities through committees including Nomination and Remuneration, Audit and Risk, and Clinical Committees [S1].
• The company has onboarded over 25 transplant centers for Ryoncil® since launch, with coverage expanding to over 250 million US lives insured by commercial and government payers, including mandatory Medicaid coverage in all US states as of July 2025 [S1].